AMANDA THOMPSON: Open Payments
NPI 1891129854 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,188 in 93 payments from 9 companies in 2025. Trend: 2023 $1,021 · 2024 $918 · 2025 $2,188
Food & beverage: $2,188
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 24 | $495 |
| Janssen Pharmaceuticals, Inc | 10 | $427 |
| E.R. Squibb & Sons, L.L.C. | 11 | $356 |
| Alkermes, Inc. | 16 | $249 |
| Vanda Pharmaceuticals Inc. | 8 | $205 |
| Otsuka America Pharmaceutical, Inc. | 9 | $169 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $165 |
| Teva Pharmaceuticals USA, Inc. | 3 | $64 |
| ABBVIE INC. | 3 | $57 |
Products named: INGREZZA, INVEGA SUSTENNA, COBENFY, FANAPT, CAPLYTA, ARISTADA, REXULTI, VIVITROL.
Industry payments across CA — which companies pay providers there.
